Blueprint Medicines Corp’s filing revealed that its CHIEF OPERATING OFFICER Rossi Christina unloaded Company’s shares for reported $0.23 million on May 05 ’25. In the deal valued at $101.75 per share,2,274 shares were sold. As a result of this transaction, Rossi Christina now holds 66,992 shares worth roughly $6.81 million.
Then, Hurley Ariel sold 2,752 shares, generating $283,819 in total proceeds. Upon selling the shares at $103.13, the PRINCIPAL ACCOUNTING OFFICER now owns 16,944 shares.
Before that, ARIEL HURLEY bought 2,942 shares. Blueprint Medicines Corp shares valued at $307,851 were divested by the Officer at a price of $104.64 per share.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Jefferies began covering BPMC with “Buy” recommendation on March 17, 2025. Scotiabank started covering the stock on March 07, 2025. It rated BPMC as “a Sector outperform”.
Price Performance Review of BPMC
On Friday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 2.21% to $101.69. Over the last five days, the stock has gained 4.65%. Blueprint Medicines Corp shares have risen nearly 16.59% since the year began. Nevertheless, the stocks have fallen -3.57% over the past one year. While a 52-week high of $121.90 was reached on 01/27/25, a 52-week low of $73.04 was recorded on 04/09/25. SMA at 50 days reached $89.95, while 200 days put it at $93.23.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 99.99, which if violated will result in even more drops to 98.28. On the upside, there is a resistance level at 102.79. A further resistance level may holdings at 103.88. The Relative Strength Index (RSI) on the 14-day chart is 63.57, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.21, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 17.77%. Stochastics %K at 72.85% indicates the stock is a holding.
The most recent change occurred on November 14, 2024 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $126 price target.
